TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
03/21/2025
Back to search
Official data from USPTO
MORPHOSYS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
MORPHOSYS
ST13
US500000097042228Class
1, 5, 42
Filing
97042228
Registration
7071326
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
30
Latest update
03/26/2025
Trademark type
Word
Nice classes
1, 5, 42
Filing date
09/23/2021
Registration date
06/06/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/06/2023
Last transaction
03/26/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
Drawing code
4
Owner type
99
Owner location
Planegg, DE
Examiner
WANG, YUAN YUAN
Law office
L90
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
MorphoSys AG
Representatives
Maury M. Tepper, III Tepper & Eyster, PLLC
Technical classification
Nice Classes
Class 1Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
reagents for scientific and medical research for use in the research and production of small molecule pharmaceuticals; active pharmaceutical ingredientsantibodiesproteins and small molecules for use in the manufacture of pharmaceuticalsbiopharmaceuticalsvaccinesfinished drug products; antibodies for use in the manufacture of active ingredients of pharmaceuticals and vaccines
Class 5
pharmaceutical preparations for the treatment of diseases that involve dysregulation of epigenetic pathways; pharmaceutical preparations for epigenetic modulators as therapeutics; pharmaceuticals comprising small molecules for the treatment and prevention of metabolic disordersinfectious diseasescancerinflammatory diseasesAlzheimer'ssepsisrestenosis; small molecule compounds for use as drug delivery agents in pharmaceuticals; small molecule compounds being pharmaceuticals for the treatment and prevention of diseases and disordersmetabolic disordersinfectious diseasescancerinflammatory diseasesAlzheimer'ssepsisrestenosis in humans; small molecule pharmaceuticals for the treatment of diseases and conditionsmetabolic disordersinfectious diseasescancerinflammatory diseasesAlzheimer'ssepsisrestenosis; Pharmaceuticals and pharmaceutical preparations for human use for the treatment and prevention of diseases and disordersmetabolic disordersinfectious diseasescancerinflammatory diseasesAlzheimer'ssepsisrestenosis; antibodies sold as a component ingredient of pharmaceuticals for the treatment of metabolic disordersinfectious diseasescancerinflammatory diseasesAlzheimer'ssepsisrestenosis; diagnostic preparations for medical purposes; biological substances for human medical diagnostics and analysis for the treatment of metabolic disordersinfectious diseasescancerinflammatory diseasesAlzheimer'ssepsisrestenosis; Clinical medical reagents; Biological preparations for medical purposesfor the treatment of metabolic disordersinfectious diseasescancerinflammatory diseasesAlzheimer'ssepsisrestenosis; pharmaceutical and veterinary preparationsagents and substances for the treatment of metabolic disordersinfectious diseasescancerinflammatory diseasesAlzheimer'ssepsisrestenosis
Class 42
Pharmaceutical research and development of pharmaceutical preparationsmedicines and vaccines; providing medical and scientific research information; Scientific research in the nature of conducting clinical trials for others; scientific and technological servicesscientific researchanalysistesting services in the fields of analytical chemistrybiochemistrymedicinal chemistrydrug developmentbiotechnologymicrobiology and molecular biology; research and design servicesresearch and development in the field of antibodies and clinical research in connection with the treatment and prevention of metabolic disordersinfectious diseasescancerinflammatory diseasesAlzheimer'ssepsisrestenosis
Publications
History of USPTO decisions and trademark events.
30 publications found
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
03/21/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
03/21/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
03/21/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
03/21/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
03/21/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
06/06/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
06/06/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/21/2023
PUBO
PUBLISHED FOR OPPOSITION
03/21/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/01/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/13/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
02/10/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
02/10/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
02/10/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
02/10/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
02/01/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
02/01/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
02/01/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
02/01/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/10/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/10/2023
ALIE
ASSIGNED TO LIE
01/09/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/11/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
06/27/2022
GNRT
NON-FINAL ACTION E-MAILED
06/27/2022
CNRT
NON-FINAL ACTION WRITTEN
06/27/2022
DOCK
ASSIGNED TO EXAMINER
06/24/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/25/2021
NWAP
NEW APPLICATION ENTERED
09/27/2021
Continuous trademark protection
Get notified about every new filing that threatens MORPHOSYS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.